MiMedx Group, Inc. (MDXG)
4.57
+0.14
(+3.16%)
USD |
NASDAQ |
Sep 04, 16:00
4.565
0.00 (0.00%)
After-Hours: 20:00
MiMedx Group SG&A Expense (TTM) : 255.08M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 255.08M |
| March 31, 2026 | 259.46M |
| December 31, 2025 | 266.19M |
| September 30, 2025 | 254.16M |
| June 30, 2025 | 238.68M |
| March 31, 2025 | 229.93M |
| December 31, 2024 | 225.09M |
| September 30, 2024 | 218.40M |
| June 30, 2024 | 217.45M |
| March 31, 2024 | 214.01M |
| December 31, 2023 | 211.13M |
| September 30, 2023 | 206.73M |
| June 30, 2023 | 207.63M |
| March 31, 2023 | 211.47M |
| December 31, 2022 | 208.79M |
| September 30, 2022 | 211.91M |
| June 30, 2022 | 204.72M |
| March 31, 2022 | 202.53M |
| December 31, 2021 | 198.36M |
| September 30, 2021 | 194.00M |
| June 30, 2021 | 195.76M |
| March 31, 2021 | 179.48M |
| December 31, 2020 | 181.02M |
| September 30, 2020 | 177.76M |
| June 30, 2020 | 180.97M |
| Date | Value |
|---|---|
| March 31, 2020 | 194.28M |
| December 31, 2019 | 198.20M |
| September 30, 2019 | 152.76M |
| June 30, 2019 | 160.24M |
| March 31, 2019 | 177.18M |
| December 31, 2018 | 192.23M |
| September 30, 2018 | 243.85M |
| June 30, 2018 | 245.35M |
| March 31, 2018 | 233.08M |
| December 31, 2017 | 220.12M |
| September 30, 2017 | 216.90M |
| June 30, 2017 | 204.84M |
| March 31, 2017 | 192.30M |
| December 31, 2016 | 180.00M |
| September 30, 2016 | 168.12M |
| June 30, 2016 | 154.84M |
| March 31, 2016 | 144.72M |
| December 31, 2015 | 133.38M |
| September 30, 2015 | 126.10M |
| June 30, 2015 | 115.39M |
| March 31, 2015 | 103.94M |
| December 31, 2014 | 90.48M |
| September 30, 2014 | 75.51M |
| June 30, 2014 | 64.03M |
| March 31, 2014 | 53.71M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Anika Therapeutics, Inc. | 52.67M |
| Perspective Therapeutics, Inc. | 29.46M |
| ABVC BioPharma, Inc. | 6.400M |
| Enovis Corp. | 1.081B |
| Edwards Lifesciences Corp. | 2.201B |